Published clinical trials on PD-1 blockade in LA-NPC
| First author (identifier) | Phase | Sample size (E/C) | Experimental group | Control group | Primary endpoint [HR (95% CI); P]* | OS [HR (95% CI); P]* | Tolerability | QoL |
|---|---|---|---|---|---|---|---|---|
| Liu et al.1 (NCT03700476) | 3 | 425 (210/215) | IP: sintilimab 200 mg + GP, q3w × 3; RP: DDP, q3w × 2 + sintilimab 200 mg, q3w × 3 + IMRT; AP: sintilimab 200 mg, q3w × 6 | Same as the experimental group, but without sintilimab | EFS: 3-year rate, 86.0% vs. 76.0% [0.59 (0.38–0.92); 0.019] | 3-year rate, 92% vs. 92% [0.86 (0.50–1.49); 0.60] | No | Yes |
| Liang et al.2 (NCT03427827) | 3 | 450 (226/224) | IP: GP, q3w × 3; RP: DDP, q3w × 2 + IMRT; AP: camrelizumab 200 mg, q3w × 12 | Same as the experimental group, but without camrelizumab | EFS: 3-year rate, 86.9% vs. 77.3% [0.56 (0.36–0.89); 0.01] | 3-year rate, 96.4% vs. 92.9% [0.80 (0.35–1.82); 0.59] | No | Yes |
| Liu et al.3 (NCT03925090) | 2 | 150 (100/50) | IP: toripalimab 240 mg, q2w × 2; RP: DDP, q3w × 3 + IMRT; AP: toripalimab 240 mg, q3w × 8 | Same as the experimental group, but without toripalimab | PFS: 2-year rate, 92.0% vs. 74.0% [0.40 (0.18–0.89); 0.019] | 3-year rate, 99.0% vs. 90.0% (NR) | No | Yes |
| Xu et al.4 (NCT04907370) | 3 | 532 (267/265) | IP: toripalimab 240 mg + GP, q3w × 3; RP: toripalimab 240 mg, q3w × 3 + IMRT; AP: toripalimab 240 mg, q3w × 11 | Same as the experimental group, but with concurrent DDP | FFS: 3-year rate, 88.3% vs. 87.6% [0.92 (0.66–1.79); 0.73] | 3-year rate, 96.1% vs. 96.5% [1.04 (0.52–2.08); 0.81] | Yes | Yes |
| Xu et al.5 (NCT03984357) | 2 | 152 (152/NA) | IP: nivolumab 360 mg + GP, q3w × 3; RP: nivolumab 360 mg, q3w × 3 + IMRT; AP: nivolumab 480 mg, q4w × 6 | NA | FFS: 3-year rate, 88.5% | 3-year rate, 97.9% | Yes | Yes |
| You et al.6 (NCT04453826) | 3 | 390 (194/196) | IP: GP, q3w × 3; RP: DDP + camrelizumab 200 mg, q3w × 2 + IMRT; AP: camrelizumab 200 mg, q3w × 17 | Same as the experimental group, but without camrelizumab | PFS: 3-year rate, 83.4% vs. 71.3% [0.51 (0.34–0.77); 0.001] | 3-year rate, 94.8% vs. 92.2% [0.59 (0.27–1.28); 0.19] | No | Yes |
| Lv et al.7 (NCT04072107) | 2 | 142 (110/32) | IP: GP, q3w × 3; RP: DDP, q3w × 3 + IMRT without (RATint) or with (RAThigh) sintilimab 200 mg, q3w × 3 AP: metronomic capecitabine 650 mg/m2, p.o., bid × 6 months (RATint); sintilimab 200 mg, q3w × 9 (RAThigh) | Induction chemotherapy followed by concurrent chemoradiotherapy | FFS: 3-year rate, 89.1% vs. 74.4% [0.41 (0.23–0.75); 0.004] | 3-year rate, 96.4% vs. NR [0.57 (0.18–1.78); 0.327] | No | Yes |
| Wang et al.8 (NCT04782765) | 2 | 57 (57/NA) | IP: camrelizumab 200 mg + DP, q3w × 2; RP: DDP, q3w × 2 + IMRT; AP: camrelizumab 200 mg, q3w × 12 | NA | DFS: 3-year rate, 84.0% | 3-year rate, 89.5% | No | No |
PD-1, programmed cell death protein-1; LA-NPC, locoregionally advanced nasopharyngeal carcinoma; E/C, experimental group/control group; IP, induction phase; RP, radiotherapy phase; AP, adjuvant phase; QoL, quality of life; GP, gemcitabine-cisplatin; DDP, cisplatin; DP, docetaxel-cisplatin; IMRT, intensity-modulated radiotherapy; EFS, event-free survival; PFS, progression-free survival; FFS, failure-free survival; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not applicable; NR, not reported; q3w, once every 3 weeks; RATint, risk-adaptive therapy intermediate-risk group; RAThigh, risk-adaptive therapy high-risk group; p.o., oral administration; bid, twice per day. *Survival comparisons are presented as experimental group vs. control group, whereas for single-arm trials, survival outcomes are reported with the cohort as the experimental group, without reporting HR (95% CI) or P-values.